The NCSTN antibody targets nicastrin, a key component of the γ-secretase complex, a multisubunit protease critical for intramembrane cleavage of various transmembrane proteins. Nicastrin (NCSTN) is a type I transmembrane glycoprotein that plays a regulatory role in substrate recognition and stabilization of the γ-secretase complex, which includes presenilin, PEN-2. and APH-1. The γ-secretase complex is best known for processing amyloid precursor protein (APP), generating amyloid-β peptides implicated in Alzheimer’s disease pathogenesis. Dysregulation of NCSTN or γ-secretase activity is also linked to cancer, skin disorders, and other conditions. NCSTN antibodies are widely used in research to study the expression, localization, and function of nicastrin in cellular and disease models. They enable detection via techniques like Western blotting, immunoprecipitation, and immunofluorescence, aiding investigations into γ-secretase’s role in Notch signaling, cell differentiation, and apoptosis. Additionally, these antibodies support drug discovery efforts targeting γ-secretase in Alzheimer’s and cancer therapeutics. Recent studies also explore NCSTN mutations in familial hidradenitis suppurativa, highlighting its diverse biological and clinical relevance.